ArriVent BioPharma, Inc. - Common Stock (AVBP)

NEW YORK CITY, NY / ACCESS Newswire / October 8, 2026 / Shareholders of ArriVent BioPharma (NASDAQ:AVBP) saw between 50% and 63% of their investment's value disappear today, October 6, 2026, after the Company announced that its global Phase 3 FURVENT trial of firmonertinib did not meet its primary endpoint. If you owned AVBP shares going into this morning's announcement and lost money, you may have legal rights whether you sold today or are still holding. AVBP shareholders who suffered losses are encouraged to submit their AVBP loss details now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ArriVent BioPharma, Inc. (“ArriVent” or “the Company”) (NASDAQ: AVBP) for violations of the securities laws.

NEWTOWN SQUARE, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the first quarter ended March 31, 2024, and highlighted recent Company progress.

NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Kristine Peterson to its Board of Directors. Ms. Peterson brings over 30 years of biopharmaceutical leadership experience, and currently serves on the Boards of public companies Immunocore, Inc. and Enanta Pharmaceuticals.